# A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

> **NCT05336409** · PHASE1 · TERMINATED · sponsor: **Century Therapeutics, Inc.** · enrollment: 28 (actual)

## Conditions studied

- R/R CD19-Positive B-Cell Malignancies
- Indolent Non-Hodgkin Lymphoma
- Aggressive Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** CNTY-101
- **BIOLOGICAL:** IL-2
- **DRUG:** Lymphodepleting Chemotherapy

## Key facts

- **NCT ID:** NCT05336409
- **Lead sponsor:** Century Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-24
- **Primary completion:** 2025-07-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Strategic decision
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05336409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05336409, "A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05336409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*